Intestinal failure is defined by dependence on parenteral nutrition for survival. Understanding its classification, causes, and the stepwise path from intestinal rehabilitation to transplantation is essential for GI and transplant fellows — and rare enough that most clinicians learn it poorly.
Classify intestinal failure by type (I, II, III) and identify the most common causes in each category
Describe the stepwise approach from intestinal rehabilitation to intestinal transplantation, including teduglutide candidacy
Identify the indications for isolated intestinal versus multivisceral transplantation
24 min · 6 sectionsIntestinal
Reading mode
On this page
01Definition & Classification
02Etiology
03Parenteral Nutrition — Sustaining and Stressing
04Intestinal Rehabilitation
05Transplant Evaluation
06Outcomes & Clinical Application
Progress0/6
ESPEN Definition of Intestinal Failure
Intestinal failure (IF) is defined as reduction of functional gut mass below the minimum necessary to absorb sufficient macronutrients and/or water and electrolytes, such that intravenous supplementation is required to maintain health and/or growth. This distinguishes IF from simple malabsorption — IF implies dependence on parenteral nutrition (PN) as a life-sustaining intervention, not merely a nutritional supplement.
Resolves with supportive care; brief PN exposure; no chronic complications
Type II
Prolonged acute — weeks to months (anastomotic breakdown, enterocutaneous fistula, major abdominal catastrophe)
Requires multidisciplinary IF team; often reversible with surgical and nutritional management
Type III
Chronic, stable, not reversible — requires lifelong home PN
Primary setting for intestinal transplant evaluation; cumulative IFALD risk over months to years
Quick recall
1/2
What is the defining characteristic that distinguishes intestinal failure from intestinal insufficiency or simple malabsorption?
Tap to reveal →
Short bowel syndrome (SBS) is the most common cause of chronic IF, resulting from massive small intestinal resection leaving insufficient absorptive surface. IF generally occurs when <100–150 cm of functional small intestine remains (normal ~600 cm), though absorptive capacity varies by segment and whether the colon is intact.
Cause
Notes
— ADULTS —
Mesenteric ischemia (acute SMA occlusion)
Most common adult cause; catastrophic single event with massive bowel loss; often elderly patients
Crohn's disease (cumulative resections)
Most common in young adults; repeated resections over years — each removes functional length
Volvulus
Midgut volvulus can destroy most of the small bowel; requires urgent resection
Radiation enteritis
Late complication of pelvic/abdominal radiation; chronic, progressive bowel dysfunction and strictures
Trauma
High-velocity mechanism; rare cause of SBS in adults
— PEDIATRIC —
Necrotizing enterocolitis (NEC)
Most common indication for intestinal transplant in children; bowel necrosis in premature neonates requiring emergency resection
Gastroschisis
Abdominal wall defect; gut exposed and susceptible to vascular compromise → loss of bowel length
Intestinal atresia
Congenital; may require extensive resection at birth
Neonatal volvulus
Midgut volvulus in infancy; can result in total loss of midgut
Other etiologies of chronic IF: Chronic intestinal pseudo-obstruction (CIPO) — dysmotility disorder with anatomically intact but functionally non-operative bowel; often requires multivisceral transplant given global gut dysmotility. Mucosal disease (microvillous inclusion disease, tufting enteropathy) — congenital absorptive failure from birth; primary indications for pediatric intestinal transplant in this subgroup.
Quick recall
1/2
A 54-year-old develops short bowel syndrome after mesenteric ischaemia resection (60 cm jejunum remaining). He is 4 months into home PN with recurrent CVC infections. When and why should he be referred to an intestinal transplant centre?
Tap to reveal →
Long-term PN is life-sustaining but carries serious complications with chronic use. Each complication should be anticipated, screened for, and managed proactively. Complications accumulate over years and are the primary drivers of intestinal transplant referral.
Complication
Key Points
Catheter-related bloodstream infection (CRBSI)
Leading complication; recurrent CRBSIs exhaust venous access sites and accelerate hepatic injury; Gram-positive organisms most common (S. aureus, CoNS); fungemia = urgent transplant indication
Long-term central lines → progressive thrombosis; each site lost limits future PN delivery; ≥2 of 6 sites lost = transplant referral threshold
Metabolic bone disease
Hypovitaminosis D, calcium malabsorption, PN-induced metabolic acidosis → osteoporosis; routine DEXA screening at experienced IF centers
Renal oxalate nephrolithiasis
Fat malabsorption → calcium binds intraluminal fat instead of oxalate → increased free oxalate absorption → renal stones; most common in colon-intact SBS patients
Quality of life burden
12–16 hours/night infusions; sleep disruption, social isolation, employment limitations; depression and anxiety are common and underrecognized
Central Venous Access Mapping — Critical at Every Encounter
Document all patent and occluded central venous sites at every encounter. Major sites: bilateral subclavian, internal jugular, and femoral veins (6 total). Occlusion of ≥2 sites triggers urgent transplant referral regardless of liver disease status or CRBSI history. Loss of all access means PN can no longer be delivered — it is life-threatening.
Quick recall
1/2
Why is fungemia (Candida CRBSI) specifically cited as an urgent transplant indication, distinct from bacterial CRBSI?
Tap to reveal →
Intestinal transplant is not first-line. Every patient with Type III IF should complete a structured rehabilitation program — the goal is to maximize enteral function, reduce PN dependence, and prevent access and hepatic complications.
Dose: 0.05 mg/kg/day subcutaneous injection once daily
STEPS trial (Jeppesen, Gastroenterology 2012, PMID 22982184): 63% of teduglutide-treated patients achieved ≥20% PN volume reduction vs. 30% with placebo (p=0.002)
Screening: colonoscopy with polyp removal required before initiation and every 5 years — GLP-2 promotes mucosal cell proliferation
Contraindications: active/recent GI malignancy within 5 years; active Crohn's with stricture or obstruction
Strategy 4
Surgical Reconstruction
STEP procedure (Serial Transverse Enteroplasty): stapled tapering of dilated, dysmotile bowel to lengthen and taper functional segment; can be repeated; most common autologous reconstruction today
Bianchi procedure (LILT): divides bowel longitudinally to create two parallel channels; less commonly performed
Indication: dilated dysmotile segment with bacterial overgrowth; primarily pediatric; can restore significant function before transplant listing
Not all patients who fail rehabilitation are transplant candidates — active malignancy, uncontrolled systemic infection, severe cardiopulmonary disease, and social contraindications preclude listing. Rehabilitation also identifies patients who can achieve PN independence without transplant.
Quick recall
1/2
What is the mechanism of teduglutide, and what colonoscopy monitoring is required before initiating it?
Tap to reveal →
Intestinal transplant is reserved for patients with chronic IF failing PN — when PN itself can no longer be delivered safely or when its complications are life-threatening. Referral should occur early, before venous access is exhausted and before IFALD progresses to decompensated cirrhosis.
Indications for Listing
Indication
Clinical Threshold
Loss of central venous access
≥2 of 6 major central venous sites occluded (bilateral subclavian, IJ, femoral); cannot safely deliver PN — life-threatening
Recurrent life-threatening CRBSIs
≥2 hospitalizations/year for systemic sepsis; any episode of fungemia (Candida line infection)
IFALD with liver disease progression
Rising bilirubin >3 mg/dL despite PN optimization; established fibrosis, cirrhosis, or portal hypertension → combined liver-intestinal transplant required
Frequent severe dehydration
Recurrent hospitalizations for fluid and electrolyte crises despite optimized ORS and anti-motility regimen
Failed intestinal rehabilitation
After adequate teduglutide trial; persistent PN dependence incompatible with quality of life or developmental milestones (pediatric)
Volume of US Intestinal Transplant Centers
Approximately 30 centers perform intestinal transplantation in the United States — not all offer combined liver-intestinal or multivisceral procedures. UNMC and the Pittsburgh Transplant Institute are among the highest-volume programs. Early referral allows complete evaluation before the patient's condition deteriorates beyond candidacy.
Procedure Selection
Procedure
Organs Transplanted
Primary Indication
Isolated Intestinal Transplant (IT)
Small intestine (± colon)
SBS without significant IFALD; liver function preserved; most common procedure in adults
Liver-Intestinal Transplant (LIT)
Liver + small intestine (± pancreas for anatomic continuity)
SBS with IFALD causing significant liver disease; most common composite transplant in adults with hepatic involvement
Multivisceral Transplant (MVT)
Stomach + duodenum + pancreas + small intestine ± liver
Diffuse gut dysmotility (CIPO); extensive mesenteric vascular involvement; prior failed IT
Dysmotility disorder with intact liver; prior total pancreatectomy
Highest Rejection Risk of Any Solid Organ Transplant
Intestinal transplants carry the highest acute rejection rate of any solid organ transplant — the bowel contains the largest lymphoid burden of any allograft (Peyer's patches, lamina propria lymphocytes, mesenteric lymph nodes). Tacrolimus-based immunosuppression with induction agents is standard. Ileoscopy with biopsy is performed routinely post-transplant for rejection surveillance. PTLD (EBV-driven) is more common after intestinal than other solid organ transplants.
Quick recall
1/2
When IFALD is present and significant, why is isolated intestinal transplant insufficient?
Tap to reveal →
5-Year Patient Survival by Procedure (ITR Data, Experienced Centers)
Isolated IT: ~65–70% | LIT/MVT: ~55–65%
Outcomes continue to improve at high-volume centers. Primary causes of graft loss: acute and chronic rejection, PTLD, infectious complications, graft-versus-host disease. Graft survival lags patient survival — many patients survive with a failed graft and return to home PN while awaiting re-transplant.
Clinical Vignette — Venous Access Loss Triggering Transplant Listing
A 28-year-old woman with midgut volvulus at age 22 underwent near-total small bowel resection, leaving 60 cm of jejunum and an end-jejunostomy. She has been on home PN via a tunneled right internal jugular catheter for 6 years. LFTs are normal; no prior CRBSIs. She was started on teduglutide 18 months ago — weekly PN volume decreased 25% but she remains PN-dependent.
AST 22 · ALT 28 · Bili 0.6 mg/dL · New right subclavian vein thrombosis on Doppler · Right IJ previously occluded — 2 of 6 major central venous sites now lost
Work through the management step by step before the answers are revealed.
Quick recall
1/2
A patient with 45 cm of remaining jejunum (no ileocaecal valve, colon in continuity) has 3.5 L/day stomal output and is losing weight. What are the immediate management priorities, and how does the colon-in-continuity anatomy guide dietary strategy?
Tap to reveal →
References
Pironi L, Boeykens K, Bozzetti F, et al. ESPEN practical guideline: Home parenteral nutrition. Clin Nutr. 2023;42(3):411-430. PubMed 36796121
Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473-1481. PubMed 22982184(STEPS pivotal trial)
Schwartz LK, O'Keefe SJ, Fujioka K, et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol. 2016;7(2):e142. doi:10.1038/ctg.2015.69. PubMed 26844839(STEPS-2 long-term extension — source of the enteral-autonomy figure)
Abu-Elmagd KM, Kosmach-Park B, Costa G, et al. Long-term survival, nutritional autonomy, and quality of life after intestinal and multivisceral transplantation. Ann Surg. 2012;256(3):494-508. PubMed 22868368